20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters

BACKGROUND: Approximately 5–8% of melanoma patients will develop in-transit metastases (IT-mets). Tumor necrosis factor-α (TNF) and melphalan-based isolated limb perfusion (TM-ILP) is an attractive treatment modality in melanoma patients with multiple IT-mets. This study reports on a 20 years experi...

Descripción completa

Detalles Bibliográficos
Autores principales: Deroose, Jan P., Eggermont, Alexander M. M., van Geel, Albertus N., de Wilt, Johannes H. W., Burger, Jacobus W. A., Verhoef, Cornelis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Melanomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264869/
https://www.ncbi.nlm.nih.gov/pubmed/21879272
http://dx.doi.org/10.1245/s10434-011-2030-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264869/
https://www.ncbi.nlm.nih.gov/pubmed/21879272
http://dx.doi.org/10.1245/s10434-011-2030-7

Ejemplares similares